Skip to main content
LLY
NYSE Life Sciences

FDA Approves Mounjaro to Cut Heart Risk in Type 2 Diabetes

Tom Rudovsky · Reported by PR Newswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1,180
Mkt Cap
$1.107T
52W Low
$712.05
52W High
$1,292.65
52W Position info
66% above low
Off High info
8.7% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

LLY sits 66% above its 52-week low of $712.05.

Summary

The FDA approved Mounjaro (tirzepatide) to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk. This is the first GIP/GLP-1 receptor agonist cleared for this indication, expanding the drug's label beyond glucose control and weight loss. The approval is based on SURPASS-CVOT, a 13,000-patient trial showing non-inferiority to Trulicity with an 8% lower MACE-3 rate (HR 0.92). Mounjaro is already the #1 prescribed branded type 2 diabetes medicine in the U.S., and this label expansion addresses the leading cause of death in that population. The news follows Lilly's Q2 report showing 48% revenue growth driven by Mounjaro and Zepbound, reinforcing the franchise's momentum.

At the time of this announcement, LLY was trading at $1,180.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 04, 2026, 1:53 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,416.54
Real-time Price: $1,366.76 info
Change: -$49.78 (-4%) info
Market Cap: $1.284T info
LLY
Oct 29, 2026, 3:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1,368.10
Real-time Price: $1,366.76 info
Change: -$1.34 (-0.10%) info
Market Cap: $1.284T info
LLY
Oct 29, 2026, 12:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1,370.30
Real-time Price: $1,366.76 info
Change: -$3.54 (-0.26%) info
Market Cap: $1.284T info
LLY
Oct 29, 2026, 11:35 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1,363.50
Real-time Price: $1,366.76 info
Change: +$3.26 (+0.24%) info
Market Cap: $1.284T info
LLY
Oct 29, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1,344.00
Real-time Price: $1,366.76 info
Change: +$22.76 (+2%) info
Market Cap: $1.284T info